Bicarbonate Purge Solution to Support Impella Devices for Patients with Clinically Suspected or Confirmed Heparin-induced Thrombocytopenia

Jeremy Moretz
Soumen Das
Craig Beavers
Doug Jennings
Jenna F. Cox

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/pharmacy_mtgabstracts

Recommended Citation

This Conference Proceeding is brought to you for free and open access by the Pharmacy at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Pharmacy Meeting Abstracts by an authorized administrator of Henry Ford Health System Scholarly Commons.
Authors
Jeremy Moretz, Soumen Das, Craig Beavers, Doug Jennings, Jenna F. Cox, Robert DiDomenico, Steve Dunn, Long To, Toby Trujillo, Phillip Weeks, and Scott Corbett
EPCardiac41

Bicarbonate Purge Solution To Support Impella Devices For Patients With Clinically Suspected Or Confirmed Heparin-induced Thrombocytopenia

Jeremy Moretz, PharMD, Soumen Das, PhD, Craig Beavers, PharmD, Doug Jennings, PharMD, Jenna F. Cox, PharMD, Robert DiDomenico, PharMD, Steve Dunn, PharmD, Long To, PharmD, Toby Trujillo, PharmD, Phillip Weeks, PharmD, Scott Corbett, PhD; 1Abiomed, Danvers, MA, USA, 2University of Kentucky College of Pharmacy, Lexington, KY, USA, 3Long Island University College of Pharmacy, Brooklyn, NY, USA, 4Prisma Health Richland Hospital, Columbia, SC, USA, 5UIC College of Pharmacy, Chicago, IL, USA, 6University of Virginia Health System, Charlottesville, VA, USA, 7Henry Ford Health System, Detroit, MI, USA, 8University of Colorado Skaggs School of Pharmacy, Aurora, CO, USA, 9Memorial Hermann Texas Medical Center, Houston, TX, USA

Study: The Impella catheter is a transvalvular, micro-axial left ventricular assist device that provides temporary mechanical circulatory support and requires a heparin-containing purge solution to reduce the risk of biomaterial deposition in the purge gaps and also maintain proper pump function. For patients with suspected or confirmed heparin-induced thrombocytopenia (HIT), direct thrombin inhibitors (DTI) have been proposed as an alternative to heparin in the purge, but have been associated with pump failure requiring temporary TPA in the purge solution to normalize pump function. In this report, we review HIT patients supported with a sodium bicarbonate-based purge solution (BBPS).

Methods: Patients with suspected or confirmed HIT on Impella support using sodium bicarbonate (25 mEq in 1L D5W solution) in the purge from September 2020 to January 2021 were reviewed. Case data were obtained from Impella Quality (IQ) database for those supported with a BBPS and clinically suspected or confirmed HIT. Purge pressures and purge flows were evaluated from the Automated Impella Controller (AIC). Ten patients were supported with a BBPS during this period. Impella support was begun either with no anticoagulant (n=5), DTI (n=2), or heparin (n=3) and then switched to BBPS. Impella run time using a BBPS ranged from 1-14 days; five pumps had a run time with a BBPS > 10 days (Figure 1). Systemic DTI use was used in five cases along with a BBPS. No purge pathway thrombosis or bleeding events were observed, along with no changes in purge flow or purge pressures observed. In conclusion, preliminary experience suggests the use of BBPS in the setting suspected or confirmed HIT patients supported with an Impella is safe and effective and may provide a useful therapeutic option for heparin intolerant patients. Future work should investigate mechanisms and purge reliability of BBPS in this setting.

EPCardiac42

Percutaneous Access Device For Preventing LVAD Driveline Infection

Tadashi Motomura, MD, PhD, Shinsaku Koarashi, None, Nozomi Koike, None, Kenji Yamazaki, MD, PhD, Yasuyuki Shiraishi, PhD, Tonomori Yambe, MD, PhD, Evaheart, Inc., Houston, TX, USA, Hi-Lex Corp, Takarazuka, Japan, Sun Medical Technology Corp., Suwa-shi, Japan, Hokkaido CV Hospital, Sapporo, Japan, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

Study: A durable left ventricular assist device (LVAD) requires long-term circulatory support capability, yet driveline infection (DLI) due to the percutaneous driveline access is an inevitable adverse event, which is one of the major causes of hospital readmission impeding the patient quality of life. Totally implantable system with a percutaneous energy transmission system may be an ultimate solution for this adverse event, but another potential approach historically attempted is a percutaneous access device (PAD).

Methods: PAD prototypes were fabricated for the in-vitro fitting tests, handling feasibility, and, in-vivo implantation tests. Control smooth surface (non-textured titanium surface), blasted rough surface, multiple sintered beads surface, and 3D-titanium sponge material was evaluated in tissue healing and integrity between skin-titanium interface. To identify the optimal animal model and chronic study protocol, working prototypes with sealed mechanism were designed based upon an anatomical fitting study (on the bovine study) and evaluated with goat and swine models (Mexican hairless and Göttingen mini pig) for chronic implantation. After termination, histopathology analysis was performed.

Results: Non-textured titanium surface developed poor tissue adhesion and developed epidermal down-growth. Titanium beads (spherical/asymmetrical) sintered surface establish better tissue ingrowth but inflammatory cell infiltration was sustained around the skin interface. Titanium sponge structure appeared to develop stable skin and subcutaneous healing without the evidence of active inflammation and infection on the Göttingen minipig model up to 60 days chronics implantation. Histopathology study demonstrated tight tissue adhesion and micro vascularization. Skin button PAD may be a potential technology for preventing DLI by offering mechanical barriers for the driveline exit site avoiding bacterial invasion from the interface between the driveline and adjacent tissue.